Showing 21-25 of 42 outcomes & condition management:
A new approach for post-marketing safety studies

BioPharma Dive Online April 4, 2022 Read the Full Article >>   The large quantity of digitized healthcare data in the U.S., combined with advancements in data collection and processing technologies, present an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted. The Traditional Approach Post-marketing safety studies are a[…]

OM1 Launches New Mental Health and Neuroscience Real-World Data Network

Read the Press Release>>   BOSTON, March 31, 2022 /PRNewswire/ — OM1, a leading technology enabled real-world data and artificial intelligence (AI) company with a focus on delivering insights into multiple chronic diseases, today announces the launch of its Mental Health and Neuroscience Specialty Area led by physician and entrepreneur, Dr. Carl D. Marci. The division includes new data on psychiatric[…]

Dell Medical School helps develop artificial intelligence tool for knee surgery

April 2, 2021 – Austin American-Statesman Read the Full Article >> If you had osteoarthritis in your knee, how would you know when it’s the right time to have knee replacement surgery? Dell Medical School at the University of Texas helped patients at UT Health Austin’s Musculoskeletal Institute answer that question by studying a new artificial intelligence tool[…]

OM1 Launches Multiple Sclerosis Registry With More Than 20,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, July 14, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry. MS is an auto-immune, inflammatory disease that attacks the central nervous system (CNS) and causes a variety of neurological symptoms, such as muscle weakness, spasticity, fatigue, numbness, vision[…]

1 3 4 5 6 7 9